Table S1 AJCC-Stage made a high degree of collinearity with AJCC-T, AJCC-N, AJCC-M, and grade

	AJCC-Stage I (n=278)	AJCC-Stage II (n=600)	AJCC-Stage III (n=14)	AJCC-Stage IV (n=165)	χ^2 value	Р
AJCC-T1	144 (51.8%)	255 (42.5%)	0 (0.0%)	34 (20.6%)	545.48	<0.001
AJCC-T2	131 (47.1%)	344 (57.3%)	0 (0.0%)	119 (72.1%)		
AJCC-T3	3 (1.1%)	1 (0.2%)	14 (100.0%)	12 (7.3%)		
AJCC-N0	278 (100.0%)	600 (100.0%)	14 (100.0%)	149 (90.3%)	87.83	< 0.001
AJCC-N1	0 (0.0%)	0 (0.0%)	0 (0.0%)	16 (9.7%)		
AJCC-M0	278 (100.0%)	600 (100.0%)	14 (100.0%)	9 (5.5%)	989.36	<0.001
AJCC-M1	0 (0.0%)	0 (0.0%)	0 (0.0%)	156 (94.5%)		
Grade unknown	78 (28.1%)	0 (0.0%)	0 (0.0%)	25 (15.2%)	966.79	< 0.001
Grade I	129 (46.4%)	0 (0.0%)	0 (0.0%)	2 (1.2%)		
Grade II	71 (25.5%)	0 (0.0%)	0 (0.0%)	6 (3.6%)		
Grade III	0 (0.0%)	212 (35.3%)	5 (35.7%)	60 (36.4%)		
Grade IV	0 (0.0%)	388 (64.7%)	9 (64.3%)	72 (43.6%)		

The result of chi-squared test revealed that AJCC-Stage was linearly correlated with AJCC-T, AJCC-N, AJCC-M, and grade (all P<0.05). AJCC, the American Joint Committee on Cancer.

Table S2 The relationshi	between radiotherapy/chemotherapy and clinicopathological characteristics	5

	Radioth	erapy			Chemo	therapy		
Characteristics	None/unknown (n=986)	Yes (n=71)	χ ² value ^a /T ^a	P ^a	No/unknown (n=159)	Yes (n=898)	χ ² value ^b /T ^l	° P⁵
Age (years)	24.50±17.32	34.54±18.19	-4.701	*<0.001	39.05±20.81	22.72±15.69	9.433	*<0.001
Sex			1.241	0.265			2.142	0.143
Male	544 (55.2%)	44 (62.0%)			80 (50.3%)	508 (56.6%)		
Female	442 (44.8%)	27 (38.0%)			79 (49.7%)	390 (43.4%)		
Race			1.946	0.584			5.969	0.113
White	758 (76.9%)	51 (71.8%)			120 (75.5%)	689 (76.7%)		
Black	138 (14.0%)	13 (18.3%)			30 (18.9%)	121 (13.5%)		
Asian or Pacific Islander	81 (8.2%)	7 (9.9%)			9 (5.7%)	79 (8.8%)		
American Indian	9 (0.9%)	0 (0%)			0 (0%)	9 (1.0%)		
Marital status			14.775	*0.001			81.745	*<0.001
Single	753 (76.4%)	40 (56.3%)			74 (46.5%)	719 (80.1%)		
Married	193 (19.6%)	27 (38.0%)			69 (43.4%)	151 (16.8%)		
Divorced/widowed/ separated	40 (4.1%)	4 (5.6%)			16 (10.1%)	28 (3.1%)		
ICD-O-3/pathological subtype	e		21.741	*0.016			266.681	*<0.001
9180/3	595 (60.3%)	39 (54.9%)			61 (38.4%)	573 (63.8%)		
9181/3	155 (15.7%)	20 (28.2%)			10 (6.3%)	165 (18.4%)		
9182/3	54 (5.5%)	8 (11.3%)			16 (10.1%)	46 (5.1%)		
9183/3	43 (4.4%)	1 (1.4%)			2 (1.3%)	42 (4.7%)		
9184/3	4 (0.4%)	1 (1.4%)			4 (2.5%)	1 (0.1%)		
9185/3	9 (0.9%)	0 (0.0%)			1 (0.6%)	8 (0.9%)		
9186/3	39 (4.0%)	1 (1.4%)			5 (3.1%)	35 (3.9%)		
9187/3	2 (0.2%)	0 (0.0%)			2 (1.3%)	0 (0.0%)		
9192/3	62 (6.3%)	0 (0.0%)			47 (29.6%)	15 (1.7%)		
9193/3	18 (1.8%)	0 (0.0%)			10 (6.3%)	8 (0.9%)		
9194/3	5 (0.5%)	1 (1.4%)			1 (0.6%)	5 (0.6%)		
Primary site			144.171	*<0.001			58.552	*<0.001
Extremities	858 (87.0%)	23 (32.4%)			103 (64.8%)	778 (86.6%)		
Pelvis/spine	45 (4.6%)	14 (19.7%)			11 (6.9%)	48 (5.3%)		
Skull/mandible and others	83 (8.4%)	34 (47.9%)			45 (28.3%)	72 (8.0%)		

Table S2 (continued)

Table S2	(continued)
----------	-------------

	Radioth	erapy	_		Chemo	therapy	_	- ^k	
Characteristics	None/unknown (n=986)	Yes (n=71)	χ ² value ^a /T ^a	P ^a	No/unknown (n=159)	Yes (n=898)	χ^2 value ^b /T ^b	P⁵	
Grade			1.853	0.396			203.284	*<0.001	
Grade I/II	198 (20.1%)	10 (14.1%)			97 (61.0%)	111 (12.4%)			
Grade III/IV	691 (70.1%)	55 (77.5%)			51 (32.1%)	695 (77.4%)			
Unknown	97 (9.8%)	6 (8.5%)			11 (6.9%)	92 (10.2%)			
Laterality			125.327	*<0.001			39.873	*<0.001	
Not a paired site (axial)	65 (6.6%)	33 (46.5%)			36 (22.6%)	62 (6.9%)			
Left-origin of primary	484 (49.1%)	21 (29.6%)			63 (39.6%)	442 (49.2%)			
Right-origin of primary	437 (44.3%)	17 (23.9%)			60 (37.7%)	394 (43.9%)			
Bilateral, single primary	0 (0.0%)	0 (0.0%)			0 (0.0%)	0 (0.0%)			
AJCC-Stage			2.981	0.395			163.777	*<0.001	
I	264 (26.8%)	14 (19.7%)			107 (67.3%)	171 (19.0%)			
II	556 (56.4%)	44 (62.0%)			45 (28.3%)	555 (61.8%)			
III	14 (1.4%)	0 (0.0%)			1 (0.6%)	13 (1.4%)			
IV	152 (15.4%)	13 (18.3%)			6 (3.8%)	159 (17.7%)			
AJCC-T			16.128	*<0.001			35.322	*<0.001	
T1	388 (39.4%)	45 (63.4%)			99 (62.3%)	334 (37.2%)			
T2	570 (57.8%)	24 (33.8%)	_		58 (36.5%)	536 (59.7%)			
Т3	28 (2.8%)	2 (2.8%)			2 (1.3%)	28 (3.1%)			
AJCC-N			3.754	0.053			2.877	0.090	
N0	973 (98.7%)	68 (95.8%)			159 (100%)	882 (98.2%)			
N1	13 (1.3%)	3 (4.2%)			0 (0.0%)	16 (1.8%)			
AJCC-M			0.278	0.598			17.952	*<0.001	
MO	842 (85.4%)	59 (83.1%)			153 (96.2%)	748 (83.3%)			
M1	144 (14.6%)	12 (16.9%)			6 (3.8%)	150 (16.7%)			
Surgery code			27.021	*<0.001			31.155	*<0.001	
Local or partial resection	127 (12.9%)	22 (31.0%)			44 (27.7%)	105 (11.7%)			
Radical resection with limb salvage	611 (62.0%)	36 (50.7%)	-		83 (52.2%)	564 (62.8%)			
Amputation	206 (20.9%)	6 (8.5%)			25 (15.7%)	187 (20.8%)			
Forequarter/hindquarter/ hemipelvectomy	34 (3.4%)	5 (7.0%)			4 (2.5%)	35 (3.9%)			
Surgery, NOS	8 (0.8%)	2 (2.8%)			3 (1.9%)	7 (0.8%)			
Tumor size (mm)	102.18±67.51	83.21±65.51	2.292	0.022	83.77±89.79	103.94±62.33	-3.491	*0.001	
Extension (mm)	35.42±14.62	42.20±16.60	-3.739	*<0.001	33.01±16.77	36.38±14.43	-2.387	*0.018	

The result of Chi-squared test or Student's t-test revealed that radiotherapy was significantly related to more T1, more local or partial resection and longer extension and so on (all P^a<0.05); chemotherapy was significantly related to Grade III/IV, less AJCC-I, more AJCC-IV, less AJCC-T1, more AJCC-M1, larger tumor size, longer extension and so on (all P^b<0.05). *, P<0.05. 9180/3 osteosarcoma NOS, 9181/3 chondroblastic osteosarcoma, 9182/3 fibroblastic osteosarcoma, 9183/3 telangiectatic osteosarcoma, 9184/3 osteosarcoma in Paget disease of bone, 9185/3 small cell osteosarcoma, 9186/3 central osteosarcoma, 9187/3 intraosseous well-differentiated osteosarcoma, 9192/3 parosteal osteosarcoma, 9194/3 high-grade surface osteosarcoma; AJCC, the American Joint Committee on Cancer; NOS, not otherwise specified.

Table S3 Multivariate analysis excluding radiotherapy and chemotherapy for cancer-specific survival in the training set

Oh ave at a visting	Multivariate analyses for CSS				
Characteristics —	HR (95% CI)	P value			
Age (years)	1.025 (1.019-1.031)	*<0.001			
Sex		0.092			
Male	1.000				
Female	0.821 (0.653-1.033)				
ICD-O-3/pathological subtype		*0.021			
9180/3 osteosarcoma (NOS)	1.000				
9181/3 chondroblastic osteosarcoma	0.953 (0.711-1.279)				
9182/3 fibroblastic osteosarcoma	0.731 (0.458-1.165)				
9183/3 telangiectatic osteosarcoma	0.744 (0.429-1.290)				
9184/3 osteosarcoma in Paget disease of bone	1.511 (0.459-4.974)				
9185/3 small cell osteosarcoma	0.244 (0.034-1.764)				
9186/3 central osteosarcoma	0.547 (0.269-1.111)				
9187/3 intraosseous well-differentiated osteosarcoma	<0.001 (<0.001-1.276E+114)				
9192/3 parosteal osteosarcoma	0.200 (0.072-0.554)				
9193/3 periosteal osteosarcoma	0.152 (0.021-1.089)				
9194/3 high-grade surface osteosarcoma	1.873 (0.595-5.900)				
Primary site		0.122			
Extremities	1.000				
Pelvis/Spine	1.379 (0.854-2.228)				
Skull/Mandible and others	0.746 (0.478-1.165)				
Grade		0.124			
Well/moderately differentiated; Grade I/II	1.000				
Poorly/undifferentiated/anaplastic; Grade III/IV	1.449 (0.999-2.102)				
Unknown	1.246 (0.750-2.071)				
AJCC-T		0.627			
T1	1.000				
T2	1.133 (0.861-1.491)				
ТЗ	0.993 (0.529-1.864)				
AJCC-N		*0.001			
NO	1.000				
N1	2.806 (1.507-5.226)				
AJCC-M		*<0.001			
МО	1.000				
M1	2.921 (2.239-3.811)				
Surgery code		0.178			
Local or partial resection	1.000				
Radical resection with limb salvage	0.768 (0.544-1.084)				
Amputation	0.919 (0.621-1.360)				
Forequarter/hindquarter/hemipelvectomy	1.262 (0.715-2.229)				
Surgery, NOS	1.290 (0.457-3.641)				
Tumor size (mm)	1.002 (1.001-1.003)	*0.001			
Extension (mm)	1.019 (1.011-1.028)	*<0.001			

*, P<0.05. We re-conducted a COX multivariate analysis excluding radiotherapy and chemotherapy, and obtained same results of predictive factors. CSS, cancer-specific survival; HR, hazard ratio; CI, confidence interval; AJCC, the American Joint Committee on Cancer; NOS, not otherwise specified.

Characteristics	Multivariate analyses for OS			
Gharacteristics	HR (95% CI)	P value		
Age (years)	1.032 (1.024-1.041)	*<0.001		
Sex		0.154		
Male	1.000			
Female	0.853 (0.685-1.061)			
Marital status		0.061		
Single	1.000			
Married	0.870 (0.622-1.216)			
Divorced/Widowed/Separated	0.490 (0.275-0.892)			
ICD-O-3/pathological subtype		*0.019		
9180/3 osteosarcoma (NOS)	1.000			
9181/3 chondroblastic osteosarcoma	0.904 (0.680-1.202)			
9182/3 fibroblastic osteosarcoma	0.850 (0.553-1.308)			
9183/3 telangiectatic osteosarcoma	0.777 (0.469-1.289)			
9184/3 osteosarcoma in Paget disease of bone	1.522 (0.538-4.304)			
9185/3 small cell osteosarcoma	0.233 (0.032-1.685)			
9186/3 central osteosarcoma	0.566 (0.289-1.105)			
9187/3 intraosseous well-differentiated osteosarcoma	<0.001 (<0.001-5.386E+107)			
9192/3 parosteal osteosarcoma	0.194 (0.070-0.535)			
9193/3 periosteal osteosarcoma	0.130 (0.018-0.926)			
9194/3 high-grade surface osteosarcoma	1.754 (0.557-5.523)			
Primary site		0.056		
Extremities	1.000			
Pelvis/Spine	1.640 (1.053-2.553)			
Skull/Mandible and others	0.903 (0.603-1.350)			
Grade		0.065		
Well/Moderately differentiated; Grade I/II	1.000			
Poorly/undifferentiated/Anaplastic; Grade III/IV	1.513 (1.021-2.292)			
Unknown	1.530 (0.853-2.456)			
AJCC-T		0.864		
T1	1.000			
Τ2	1.054 (0.812-1.367)			
ТЗ	0.936 (0.503-1.740)			
AJCC-N		*0.001		
NO	1.000			
N1	2.946 (1.598-5.431)			
AJCC-M		*<0.001		
MO	1.000			
M1	2.878 (2.221-3.727)			
Surgery code		0.153		
Local or partial resection	1.000			
Radical resection with limb salvage	0.741 (0.538-1.020)			
Amputation	0.946 (0.657-1.362)			
Forequarter/hindquarter/hemipelvectomy	1.076 (0.625-1.851)			
Surgery, NOS	0.918 (0.327-2.580)			
Tumor size (mm)	1.002 (1.001-1.003)	*<0.001		
Extension (mm)	1.020 (1.012-1.028)	*<0.001		

*, P<0.05. We re-conducted a COX multivariate analysis excluding radiotherapy and chemotherapy, and obtained same results of predictive factors. OS, overall survival; HR, hazard ratio; CI, confidence interval; AJCC, the American Joint Committee on Cancer; NOS, not otherwise specified.